Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.83 |
| ▸ | THRB | P10828 | 2/20 | 0.83 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.83 |
| ▸ | BLM | P54132 | 1/20 | 0.83 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.83 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.65 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.64 |
| ▸ | CETP | P11597 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | ASAH2 | Q9NR71 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7617846 | 1.00 | CNR2 (0.83) | CNR2THRBKCNK3ALDH1A1BLM | |
| SCHEMBL7620441 | 1.00 | CNR2 (0.83) | CNR2THRBKCNK3ALDH1A1BLM | |
| SCHEMBL7622699 | 1.00 | CNR2 (0.83) | CNR2THRBKCNK3ALDH1A1BLM | |
| SCHEMBL7617717 | 1.00 | CNR2 (0.83) | CNR2THRBKCNK3ALDH1A1BLM | |
| SCHEMBL7623460 | 1.00 | CNR2 (0.83) | CNR2THRBKCNK3ALDH1A1BLM | |
| SCHEMBL4327695 | 1.00 | CNR2 (0.83) | CNR2THRBKCNK3ALDH1A1BLM | |
| SCHEMBL4320015 | 1.00 | CNR2 (0.83) | CNR2THRBKCNK3ALDH1A1BLM | |
| SCHEMBL16909345 | 1.00 | CNR2 (0.83) | CNR2THRBKCNK3ALDH1A1BLM | |
| SCHEMBL7620523 | 1.00 | CNR2 (0.83) | CNR2THRBKCNK3ALDH1A1BLM | |
| SCHEMBL7620584 | 1.00 | CNR2 (0.83) | CNR2THRBKCNK3ALDH1A1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101247797-A | Inhibitors of anorexic lipid hydrolysis for the treatment of eating disorders | RHEOSCIENCE AS (DK) | 2008-08-20 | — | — | CN | claimed |
| US-20090054526-A1 | INHIBITORS OF ANOREXIC LIPID HYDROLYSIS FOR THE TREATMENT OF EATING DISORDERS | UNIVERSITY OF COPENHAGEN (DK) | 2009-02-26 | — | — | US | disclosed |
| CN-101247797-A | Inhibitors of anorexic lipid hydrolysis for the treatment of eating disorders | RHEOSCIENCE AS (DK) | 2008-08-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054526-A1 | INHIBITORS OF ANOREXIC LIPID HYDROLYSIS FOR THE TREATMENT OF EATING DISORDERS | LIPE, PNLIP, FAAH2 | CNR2 460/4885THRB 217/4885KCNK3 3317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.